Selective cancer targeting with prodrugs activated by histone deacetylases and a tumour-associated protease (Q39066800)

8 September 2017

title

Selective cancer targeting with prodrugs activated by histone deacetylases and a tumour-associated protease (English)

1 reference

8 September 2017

Nicole S Sampson

3

0 references

author name string

Nobuhide Ueki

series ordinal

1

1 reference

8 September 2017

Siyeon Lee

series ordinal

2

1 reference

8 September 2017

Michael J Hayman

series ordinal

4

1 reference

8 September 2017

language of work or name

English

0 references

publication date

1 January 2013

1 reference

8 September 2017

published in

Nature Communications

1 reference

8 September 2017

volume

4

1 reference

8 September 2017

page(s)

2735

1 reference

HDAC family: What are the cancer relevant targets?

8 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS3735

Genetic dissection of histone deacetylase requirement in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS3735

Anticancer activities of histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS3735

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS3735

Histone deacetylase inhibitors: Potential in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS3735

Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS3735

Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS3735

Hdac3 is essential for the maintenance of chromatin structure and genome stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS3735

Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS3735

Cysteine cathepsins in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS3735

A new pathway that regulates 53BP1 stability implicates cathepsin L and vitamin D in DNA repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS3735

Enhanced cathepsin L expression is mediated by different Ras effector pathways in fibroblasts and epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS3735

Complete nucleotide and deduced amino acid sequences of human and murine preprocathepsin L. An abundant transcript induced by transformation of fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS3735

Quantitative glycoproteomic analysis of optimal cutting temperature-embedded frozen tissues identifying glycoproteins associated with aggressive prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS3735

BRCA1 loss activates cathepsin L-mediated degradation of 53BP1 in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS3735

A cathepsin L isoform that is devoid of a signal peptide localizes to the nucleus in S phase and processes the CDP/Cux transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS3735

Increased expression and activity of nuclear cathepsin L in cancer cells suggests a novel mechanism of cell transformation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS3735

Cathepsin L proteolytically processes histone H3 during mouse embryonic stem cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS3735

Cathepsin L, target in cancer treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS3735

Role of Class I and Class II histone deacetylases in carcinoma cells using siRNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS3735

Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS3735

Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS3735

Protease-activated drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS3735

Novel colon cancer cell lines leading to better understanding of the diversity of respective primary cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS3735

TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS3735

Resistance to butyrate-induced cell differentiation and apoptosis during spontaneous Caco-2 cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS3735

A fluorogenic histone deacetylase assay well suited for high-throughput activity screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS3735

Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS3735

Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS3735

JNJ-26481585, a novel "second-generation" oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS3735

Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC-MEF2 complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS3735

Expression in mammalian cells of a gene from Streptomyces alboniger conferring puromycin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS3735

SUnSET, a nonradioactive method to monitor protein synthesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS3735

Synthesis, crystallization, and biological evaluation of an orally active prodrug of gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS3735

Imaging of protein synthesis: in vitro and in vivo evaluation of (44)Sc-DOTA-puromycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS3735

A general approach to detect protein expression in vivo using fluorescent puromycin conjugates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS3735

Enhanced cellular uptake of Ara-C via a peptidomimetic prodrug, L-valyl-ara-C in Caco-2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS3735

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NCOMMS3735

1 reference

Dimensions Publication ID

8 September 2017

0 references

1039122749

0 references

1 reference